1
|
Nagpal S, Png J, Kahouadji L, Wacker MG. A bio-predictive release assay for liposomal prednisolone phosphate. J Control Release 2024; 374:61-75. [PMID: 39089507 DOI: 10.1016/j.jconrel.2024.07.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2024] [Revised: 07/25/2024] [Accepted: 07/29/2024] [Indexed: 08/04/2024]
Abstract
Predictive performance assays are crucial for the development and approval of nanomedicines and their bioequivalent successors. At present, there are no established compendial methods that provide a reliable standard for comparing and selecting these formulation prototypes, and our understanding of the in vivo release remains still incomplete. Consequently, extensive animal studies, with enhanced analytical resolution for both, released and encapsulated drug, are necessary to assess bioequivalence. This significantly raises the cost and duration of nanomedicine development. This work presents the development of a discriminatory and biopredictive release test method for liposomal prednisolone phosphate. Using model-informed deconvolution, we identified an in vivo target release. The experimental design employed a discrete L-optimal configuration to refine the analytical method and determine the impact of in vitro parameters on the dosage form. A three-point specification evaluated the key phases of in vivo release: early (T-5%), intermediate (T-20%), and late release behavior (T-40%), compared to the in vivo release profile of the reference product, NanoCort®. Various levels of shear responses and the influence of clinically relevant release media compositions were tested. This enabled an assessment of the effect of shear on the release, an essential aspect of their in vivo deformation and release behavior. The type and concentration of proteins in the medium influence liposome release. Fetal bovine serum strongly impacted the discriminatory performance at intermediate shear conditions. The method provided deep insights into the release response of liposomes and offers an interesting workflow for in vitro bioequivalence evaluation.
Collapse
Affiliation(s)
- Shakti Nagpal
- National University of Singapore, Faculty of Science, Department of Pharmacy and Pharmaceutical Sciences, Singapore
| | - Jordan Png
- National University of Singapore, Faculty of Science, Department of Pharmacy and Pharmaceutical Sciences, Singapore
| | - Lyes Kahouadji
- Department of Chemical Engineering, Imperial College London, South Kensington Campus, SW7 2AZ London, United Kingdom
| | - Matthias G Wacker
- National University of Singapore, Faculty of Science, Department of Pharmacy and Pharmaceutical Sciences, Singapore.
| |
Collapse
|
2
|
Nagpal S, Png Yi Jie J, Malinovskaya J, Kovshova T, Jain P, Naik S, Khopade A, Bhowmick S, Shahi P, Chakra A, Bhokari A, Shah V, Gelperina S, Wacker MG. A Design-Conversed Strategy Establishes the Performance Safe Space for Doxorubicin Nanosimilars. ACS NANO 2024; 18:6162-6175. [PMID: 38359902 PMCID: PMC10906076 DOI: 10.1021/acsnano.3c08290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Revised: 01/11/2024] [Accepted: 01/12/2024] [Indexed: 02/17/2024]
Abstract
Nanomedicines exhibit multifaceted performances, yet their biopharmaceutics remain poorly understood and present several challenges in the translation from preclinical to clinical research. To address this issue and promote the production of high-quality nanomedicines, a systematic screening of the design space and in vivo performance is necessary. Establishing formulation performance specifications early on enables an informed selection of candidates and promotes the development of nanosimilars. The deconvolution of the pharmacokinetics enables the identification of key characteristics that influence their performances and disposition. Using an in vitro-in vivo rank-order relationship for doxorubicin nanoformulations, we defined in vitro release specifications for Doxil/Caelyx-like follow-on products. Additionally, our model predictions were used to establish the bioequivalence of Lipodox, a nanosimilar of Doxil/Caelyx. Furthermore, a virtual safe space was established, providing crucial insights into expected disposition kinetics and informing formulation development. By addressing bottlenecks in biopharmaceutics and formulation screening, our research advances the translation of nanomedicine from bench to bedside.
Collapse
Affiliation(s)
- Shakti Nagpal
- Department
of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, 4 Science Drive 2, Singapore 117544, Singapore
| | - Jordan Png Yi Jie
- Department
of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, 4 Science Drive 2, Singapore 117544, Singapore
| | - Julia Malinovskaya
- Dmitry
Mendeleev University of Chemical Technology of Russia, Miusskaya pl. 9, Moscow 125047, Russia
| | - Tatyana Kovshova
- Dmitry
Mendeleev University of Chemical Technology of Russia, Miusskaya pl. 9, Moscow 125047, Russia
| | - Pankaj Jain
- Sun
Pharma Advanced Research Company Ltd., 17 B Mahal Industrial Estate, Mahakali Caves Road,
Andheri (East), Mumbai, Maharashtra 400093, India
- Sun
Pharma Advanced Research Centre (SPARC), Tandalja, Vadodara, Gujarat 390 020, India
| | - Sachin Naik
- Sun
Pharma Advanced Research Company Ltd., 17 B Mahal Industrial Estate, Mahakali Caves Road,
Andheri (East), Mumbai, Maharashtra 400093, India
- Sun
Pharma Advanced Research Centre (SPARC), Tandalja, Vadodara, Gujarat 390 020, India
| | - Ajay Khopade
- Sun
Pharma Advanced Research Company Ltd., 17 B Mahal Industrial Estate, Mahakali Caves Road,
Andheri (East), Mumbai, Maharashtra 400093, India
- Sun
Pharma Advanced Research Centre (SPARC), Tandalja, Vadodara, Gujarat 390 020, India
| | - Subhas Bhowmick
- Sun
Pharma Advanced Research Company Ltd., 17 B Mahal Industrial Estate, Mahakali Caves Road,
Andheri (East), Mumbai, Maharashtra 400093, India
- Sun
Pharma Advanced Research Centre (SPARC), Tandalja, Vadodara, Gujarat 390 020, India
| | - Pradeep Shahi
- Sun
Pharma Advanced Research Company Ltd., 17 B Mahal Industrial Estate, Mahakali Caves Road,
Andheri (East), Mumbai, Maharashtra 400093, India
- Sun
Pharma Advanced Research Centre (SPARC), Tandalja, Vadodara, Gujarat 390 020, India
| | - Amaresh Chakra
- Sun
Pharma Advanced Research Company Ltd., 17 B Mahal Industrial Estate, Mahakali Caves Road,
Andheri (East), Mumbai, Maharashtra 400093, India
- Sun
Pharma Advanced Research Centre (SPARC), Tandalja, Vadodara, Gujarat 390 020, India
| | - Ashutosh Bhokari
- Sun
Pharma Advanced Research Company Ltd., 17 B Mahal Industrial Estate, Mahakali Caves Road,
Andheri (East), Mumbai, Maharashtra 400093, India
- Sun
Pharma Advanced Research Centre (SPARC), Tandalja, Vadodara, Gujarat 390 020, India
| | - Vishal Shah
- Sun
Pharma Advanced Research Company Ltd., 17 B Mahal Industrial Estate, Mahakali Caves Road,
Andheri (East), Mumbai, Maharashtra 400093, India
- Sun
Pharma Advanced Research Centre (SPARC), Tandalja, Vadodara, Gujarat 390 020, India
| | - Svetlana Gelperina
- Dmitry
Mendeleev University of Chemical Technology of Russia, Miusskaya pl. 9, Moscow 125047, Russia
| | - Matthias G. Wacker
- Department
of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, 4 Science Drive 2, Singapore 117544, Singapore
| |
Collapse
|
3
|
Akbar A, Khan S, Chatterjee T, Ghosh M. Unleashing the power of porphyrin photosensitizers: Illuminating breakthroughs in photodynamic therapy. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY. B, BIOLOGY 2023; 248:112796. [PMID: 37804542 DOI: 10.1016/j.jphotobiol.2023.112796] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/12/2023] [Revised: 09/21/2023] [Accepted: 10/01/2023] [Indexed: 10/09/2023]
Abstract
This comprehensive review provides the current trends and recent developments of porphyrin-based photosensitizers. We discuss their evolution from first-generation to third-generation compounds, including cutting-edge nanoparticle-integrated derivatives, and explores their pivotal role in advancing photodynamic therapy (PDT) for enhanced cancer treatment. Integrating porphyrins with nanoparticles represents a promising avenue, offering improved selectivity, reduced toxicity, and heightened biocompatibility. By elucidating recent breakthroughs, innovative methodologies, and emerging applications, this review provides a panoramic snapshot of the dynamic field, addressing challenges and charting prospects. With a focus on harnessing reactive oxygen species (ROS) through light activation, PDT serves as a minimally invasive therapeutic approach. This article offers a valuable resource for researchers, clinicians, and PDT enthusiasts, highlighting the potential of porphyrin photosensitizers to improve the future of cancer therapy.
Collapse
Affiliation(s)
- Alibasha Akbar
- Department of Chemistry, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India
| | - Syamantak Khan
- Department of Radiation Oncology, Stanford University, Stanford, CA, USA
| | - Tanmay Chatterjee
- Department of Chemistry, Birla Institute of Technology & Science, Pilani Hyderabad Campus, Jawahar Nagar, Kapra Mandal, Hyderabad 500078, Telangana, India
| | - Mihir Ghosh
- Department of Chemistry, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India.
| |
Collapse
|
4
|
Amiri N, Ben Taheur F, Chevreux S, Rodrigues CM, Dorcet V, Lemercier G, Nasri H. Syntheses, crystal structures, photo-physical properties, antioxidant and antifungal activities of Mg(II) 4,4′-bipyridine and Mg(II) pyrazine complexes of the 5,10,15,20 tetrakis(4–bromophenyl)porphyrin. Inorganica Chim Acta 2021. [DOI: 10.1016/j.ica.2021.120466] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
5
|
Biswasroy P, Pradhan D, Kar B, Ghosh G, Rath G. Recent Advancement in Topical Nanocarriers for the Treatment of Psoriasis. AAPS PharmSciTech 2021; 22:164. [PMID: 34041632 DOI: 10.1208/s12249-021-02057-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Accepted: 05/15/2021] [Indexed: 12/15/2022] Open
Abstract
Psoriasis is a life-threatening autoimmune inflammatory skin disease, triggered by T lymphocyte. Recently, the drugs most commonly used for the treatment of psoriasis include methotrexate (MTX), cyclosporine (CsA), acitretin, dexamethasone, and salicylic acid. However, conventional formulations due to poor absorptive capacity, inconsistent drug release characteristics, poor capability of selective targeting, poor retention of drug molecules in target tissue, and unintended skin reactions restrict the clinical efficacy of drugs. Advances in topical nanocarriers allow the development of prominent drug delivery platforms can be employed to address the critical issues associated with conventional formulations. Advances in nanocarriers design, nano-dimensional configuration, and surface functionalization allow formulation scientists to develop formulations for a more effective treatment of psoriasis. Moreover, interventions in the size distribution, shape, agglomeration/aggregation potential, and surface chemistry are the significant aspects need to be critically evaluated for better therapeutic results. This review attempted to explore the opportunities and challenges of current revelations in the nano carrier-based topical drug delivery approach used for the treatment of psoriasis.
Collapse
|
6
|
Liu Y, Fens MHAM, Capomaccio RB, Mehn D, Scrivano L, Kok RJ, Oliveira S, Hennink WE, van Nostrum CF. Correlation between in vitro stability and pharmacokinetics of poly(ε-caprolactone)-based micelles loaded with a photosensitizer. J Control Release 2020; 328:942-951. [PMID: 33098910 DOI: 10.1016/j.jconrel.2020.10.040] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2020] [Revised: 10/09/2020] [Accepted: 10/17/2020] [Indexed: 12/13/2022]
Abstract
Polymeric micelles are extensively investigated as drug delivery systems for hydrophobic drugs including photosensitizers (PSs). In order to benefit from micelles as targeted delivery systems for PS, rather than only solubilizers, the stability and cargo retention of the (PS-loaded) micelles should be properly assessed in biologically relevant media to get insight into the essential parameters predicting their in vivo performance (i.e., pharmacokinetics). In the present study, asymmetric flow field-flow fractionation (AF4) was used to investigate the in vitro stability in human plasma of empty and meta-tetra(hydroxyphenyl)chlorin (mTHPC)-loaded dithiolane-crosslinked micelles based on poly(ɛ-caprolactone)-co-poly(1,2-dithiolane‑carbonate)-b-poly(ethylene glycol) (p(CL-co-DTC)-PEG) and non (covalently)-crosslinked micelles composed of poly(ε-caprolactone)-b-poly(ethylene glycol) (pCL-PEG). AF4 allows separation of the micelles from plasma proteins, which showed that small non (covalently)-crosslinked pCL9-PEG (17 nm) and pCL15-PEG (22 nm) micelles had lower stability in plasma than pCL23-PEG micelles with larger size (43 nm) and higher degree of crystallinity of pCL, and had also lower stability than covalently crosslinked p(CL9-DTC3.9)-PEG and p(CL18-DTC7.5)-PEG micelles with similar small sizes (~20 nm). In addition, PS (re)distribution to specific plasma proteins was observed by AF4, giving strong indications for the (in)stability of PS-loaded micelles in plasma. Nevertheless, fluorescence spectroscopy in human plasma showed that the retention of mTHPC in non (covalently)-crosslinked but semi-crystalline pCL23-PEG micelles (>8 h) was much longer than that in covalently crosslinked p(CL18-DTC7.5)-PEG micelles (~4 h). In line with this, in vivo circulation kinetics showed that pCL23-PEG micelles loaded with mTHPC had significantly longer half-life values (t½-β of micelles and mTHPC was 14 and 18 h, respectively) than covalently crosslinked p(CL18-DTC7.5)-PEG micelles (t½-β of both micelles and mTHPC was ~2 h). As a consequence, long circulating pCL23-PEG micelles resulted in significantly higher tumor accumulation of both the micelles and loaded mTHPC as compared to short circulating p(CL18-DTC7.5)-PEG micelles. These in vivo data were in good agreement with the in vitro stability studies. In conclusion, the present study points out that AF4 and fluorescence spectroscopy are excellent tools to evaluate the (in)stability of nanoparticles in biological media and thus predict the (in)stability of drug loaded nanoparticles after i.v. administration, which is favorable to screen promising delivery systems with reduced experimental time and costs and without excessive use of animals.
Collapse
Affiliation(s)
- Yanna Liu
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
| | - Marcel H A M Fens
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
| | | | - Dora Mehn
- European Commission, Joint Research Centre, Ispra, Italy
| | - Luca Scrivano
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
| | - Robbert J Kok
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
| | - Sabrina Oliveira
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; Division of Cell Biology, Neurobiology and Biophysics, Department of Biology, Utrecht University, Utrecht, the Netherlands
| | - Wim E Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
| | - Cornelus F van Nostrum
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
| |
Collapse
|
7
|
Blood distribution and plasma protein binding of PHOTOCYANINE: a promising phthalocyanine photosensitizer inphaseⅡ clinical trials. Eur J Pharm Sci 2020; 153:105491. [PMID: 32726646 DOI: 10.1016/j.ejps.2020.105491] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2020] [Revised: 07/25/2020] [Accepted: 07/25/2020] [Indexed: 12/30/2022]
Abstract
Blood distribution and plasma protein binding are the important properties that can influence pharmacokinetics and ultimately the anticancer efficacy of photosensitizers in clinical photodynamic therapy. As a novel and promising phthalocyanine photosensitizer under clinical phase Ⅱ investigation in China, the superiority of PHOCYANINE is speculated on its attribution to its binding with plasma proteins. To verify this hypothesis, explore the targeting mechanism and further apply foundation for its clinical trial evaluation, we further study its in vitro and in vivo human blood distribution, in vitro plasma protein and lipoprotein binding in detail. PHOTOCYANINE was found to be mainly distributed in plasma with low KBP and KEP values. Moreover, its high binding rates to plasma proteins among various species (mouse, rat, dog, monkey, and human) were then determined. Among these plasma proteins, human serum albumin and α1-acid-glycoprotein were found to bind PHOTOCYANINE highly, and low-density lipoproteins have the highest percentage of PHOTOCYANINE over other lipoproteins. This study is expected to provide some guidance for PDT clinical evaluations and for further molecular design and development of photosensitizers.
Collapse
|
8
|
Liu Y, Fens MH, Lou B, van Kronenburg NC, Maas-Bakker RF, Kok RJ, Oliveira S, Hennink WE, van Nostrum CF. π-π-Stacked Poly(ε-caprolactone)- b-poly(ethylene glycol) Micelles Loaded with a Photosensitizer for Photodynamic Therapy. Pharmaceutics 2020; 12:pharmaceutics12040338. [PMID: 32283871 PMCID: PMC7238042 DOI: 10.3390/pharmaceutics12040338] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Revised: 04/03/2020] [Accepted: 04/06/2020] [Indexed: 12/14/2022] Open
Abstract
To improve the in vivo stability of poly(ε-caprolactone)-b-poly(ethylene glycol) (PCL-PEG)-based micelles and cargo retention by π-π stacking interactions, pendant aromatic rings were introduced by copolymerization of ε-caprolactone with benzyl 5-methyl-2-oxo-1,3-dioxane-5-carboxylate (TMC-Bz). It was shown that the incorporation of aromatic rings yielded smaller micelles (18–30 nm) with better colloidal stability in PBS than micelles without aromatic groups. The circulation time of i.v. injected micelles containing multiple pendant aromatic groups was longer (t½-α: ~0.7 h; t½-β: 2.9 h) than that of micelles with a single terminal aromatic group (t½ < 0.3 h). In addition, the in vitro partitioning of the encapsulated photosensitizer (meta-tetra(hydroxyphenyl)chlorin, mTHPC) between micelles and human plasma was favored towards micelles for those that contained the pendant aromatic groups. However, this was not sufficient to fully retain mTHPC in the micelles in vivo, as indicated by similar biodistribution patterns of micellar mTHPC compared to free mTHPC, and unequal biodistribution patterns of mTHPC and the host micelles. Our study points out that more detailed in vitro methods are necessary to more reliably predict in vivo outcomes. Furthermore, additional measures beyond π-π stacking are needed to stably incorporate mTHPC in micelles in order to benefit from the use of micelles as targeted delivery systems.
Collapse
Affiliation(s)
- Yanna Liu
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3508 TB Utrecht, The Netherlands; (Y.L.); (B.L.); (N.C.H.v.K.); (R.J.K.); (S.O.); (W.E.H.)
| | - Marcel H.A.M. Fens
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3508 TB Utrecht, The Netherlands; (Y.L.); (B.L.); (N.C.H.v.K.); (R.J.K.); (S.O.); (W.E.H.)
| | - Bo Lou
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3508 TB Utrecht, The Netherlands; (Y.L.); (B.L.); (N.C.H.v.K.); (R.J.K.); (S.O.); (W.E.H.)
| | - Nicky C.H. van Kronenburg
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3508 TB Utrecht, The Netherlands; (Y.L.); (B.L.); (N.C.H.v.K.); (R.J.K.); (S.O.); (W.E.H.)
| | - Roel F.M. Maas-Bakker
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3508 TB Utrecht, The Netherlands; (Y.L.); (B.L.); (N.C.H.v.K.); (R.J.K.); (S.O.); (W.E.H.)
| | - Robbert J. Kok
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3508 TB Utrecht, The Netherlands; (Y.L.); (B.L.); (N.C.H.v.K.); (R.J.K.); (S.O.); (W.E.H.)
| | - Sabrina Oliveira
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3508 TB Utrecht, The Netherlands; (Y.L.); (B.L.); (N.C.H.v.K.); (R.J.K.); (S.O.); (W.E.H.)
- Division of Cell Biology, Neurobiology and Biophysics, Department of Biology, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands
| | - Wim E. Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3508 TB Utrecht, The Netherlands; (Y.L.); (B.L.); (N.C.H.v.K.); (R.J.K.); (S.O.); (W.E.H.)
| | - Cornelus F. van Nostrum
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3508 TB Utrecht, The Netherlands; (Y.L.); (B.L.); (N.C.H.v.K.); (R.J.K.); (S.O.); (W.E.H.)
- Correspondence: ; Tel.: +31-620274607
| |
Collapse
|
9
|
Predicting human pharmacokinetics of liposomal temoporfin using a hybrid in silico model. Eur J Pharm Biopharm 2020; 149:121-134. [DOI: 10.1016/j.ejpb.2020.02.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Revised: 12/21/2019] [Accepted: 02/04/2020] [Indexed: 01/28/2023]
|
10
|
Liu Y, Scrivano L, Peterson JD, Fens MHAM, Hernández IB, Mesquita B, Toraño JS, Hennink WE, van Nostrum CF, Oliveira S. EGFR-Targeted Nanobody Functionalized Polymeric Micelles Loaded with mTHPC for Selective Photodynamic Therapy. Mol Pharm 2020; 17:1276-1292. [PMID: 32142290 PMCID: PMC7140040 DOI: 10.1021/acs.molpharmaceut.9b01280] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
![]()
meta-Tetra(hydroxyphenyl)chlorin
(mTHPC) is one
of the most potent second-generation photosensitizers, clinically
used for photodynamic therapy (PDT) of head and neck squamous cell
carcinomas. However, improvements are still required concerning its
present formulation (i.e., Foscan, a solution of mTHPC in ethanol/propylene
glycol (40:60 w/w)), as mTHPC has the tendency to aggregate in aqueous
media, e.g., biological fluids, and it has limited tumor specificity.
In the present study, polymeric micelles with three different diameters
(17, 24, and 45 nm) based on benzyl-poly(ε-caprolactone)-b-poly(ethylene glycol) (PCLn-PEG; n = 9, 15, or 23) were prepared with mTHPC
loadings ranging from 0.5 to 10 wt % using a film-hydration method
as advanced nanoformulations for this photosensitizer. To favor the
uptake of the micelles by cancer cells that overexpress the epidermal
growth factor receptor (EGFR), the micelles were decorated with an
EGFR-targeted nanobody (named EGa1) through maleimide-thiol chemistry.
The enhanced binding of the EGFR-targeted micelles at 4 °C to
EGFR-overexpressing A431 cells, compared to low-EGFR-expressing HeLa
cells, confirmed the specificity of the micelles. In addition, an
enhanced uptake of mTHPC-loaded micelles by A431 cells was observed
when these were decorated with the EGa1 nanobody, compared to nontargeted
micelles. Both binding and uptake of targeted micelles were blocked
by an excess of free EGa1 nanobody, demonstrating that these processes
occur through EGFR. In line with this, mTHPC loaded in EGa1-conjugated
PCL23-PEG (EGa1-P23) micelles demonstrated 4
times higher photocytotoxicity on A431 cells, compared to micelles
lacking the nanobody. Importantly, EGa1-P23 micelles also
showed selective PDT against A431 cells compared to the low-EGFR-expressing
HeLa cells. Finally, an in vivo pharmacokinetic study
shows that after intravenous injection, mTHPC incorporated in the
P23 micelles displayed prolonged blood circulation kinetics,
compared to free mTHPC, independently of the presence of EGa1. Thus,
these results make these micelles a promising nanomedicine formulation
for selective therapy.
Collapse
Affiliation(s)
- Yanna Liu
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands
| | - Luca Scrivano
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands
| | - Julia Denise Peterson
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands
| | - Marcel H A M Fens
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands
| | - Irati Beltrán Hernández
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands.,Division of Cell Biology, Department of Biology, Utrecht University, 3584 CH Utrecht, The Netherlands
| | - Bárbara Mesquita
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands
| | - Javier Sastre Toraño
- Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands
| | - Wim E Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands
| | - Cornelus F van Nostrum
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands
| | - Sabrina Oliveira
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CS Utrecht, The Netherlands.,Division of Cell Biology, Department of Biology, Utrecht University, 3584 CH Utrecht, The Netherlands
| |
Collapse
|
11
|
Yan W, Leung SS, To KK. Updates on the use of liposomes for active tumor targeting in cancer therapy. Nanomedicine (Lond) 2019; 15:303-318. [PMID: 31802702 DOI: 10.2217/nnm-2019-0308] [Citation(s) in RCA: 69] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
In the development of cancer chemotherapy, besides the discovery of new anticancer drugs, a variety of nanocarrier systems for the delivery of previously developed and new chemotherapeutic drugs have currently been explored. Liposome is one of the most studied nanocarrier systems because of its biodegradability, simple preparation method, high efficacy and low toxicity. To make the best use of this vehicle, a number of multifunctionalized liposomal formulations have been investigated. The objective of this review is to summarize the current development of novel active targeting liposomal formulations, and to give insight into the challenges and future direction of the field. The recent studies in active targeting liposomes suggest the great potential of precise targeted anticancer drug delivery in cancer therapeutics.
Collapse
Affiliation(s)
- Wei Yan
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China
| | - Sharon Sy Leung
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China
| | - Kenneth Kw To
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, PR China
| |
Collapse
|
12
|
Pires F, Santos JF, Bitoque D, Silva GA, Marletta A, Nunes VA, Ribeiro PA, Silva JC, Raposo M. Polycaprolactone/Gelatin Nanofiber Membranes Containing EGCG-Loaded Liposomes and Their Potential Use for Skin Regeneration. ACS APPLIED BIO MATERIALS 2019; 2:4790-4800. [DOI: 10.1021/acsabm.9b00524] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Filipa Pires
- CEFITEC, Physics Department, Faculty of Science and Technology, Universidade Nova de Lisboa, Campus de Caparica, 2829-516, Caparica, Portugal
| | - Jeniffer Farias Santos
- EACH, School of Arts, Sciences and Humanities, Biotechnology Laboratory, Universidade de São Paulo, 03828-000, São Paulo, Brazil
| | - Diogo Bitoque
- CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo Mártires da Pátria 130, 1169-056 Lisboa, Portugal
| | - Gabriela Araújo Silva
- CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo Mártires da Pátria 130, 1169-056 Lisboa, Portugal
| | - Alexandre Marletta
- Instituto de Física, Universidade Federal de Uberlândia, 38400-902 Uberlândia, Minas Gerais, Brazil
| | - Viviane Abreu Nunes
- EACH, School of Arts, Sciences and Humanities, Biotechnology Laboratory, Universidade de São Paulo, 03828-000, São Paulo, Brazil
| | - Paulo A. Ribeiro
- CEFITEC, Physics Department, Faculty of Science and Technology, Universidade Nova de Lisboa, Campus de Caparica, 2829-516, Caparica, Portugal
| | - Jorge Carvalho Silva
- CENIMAT/I3N, Physics Department, Faculty of Science and Technology, Universidade Nova de Lisboa, Campus de Caparica, 2829-516, Caparica, Portugal
| | - Maria Raposo
- CEFITEC, Physics Department, Faculty of Science and Technology, Universidade Nova de Lisboa, Campus de Caparica, 2829-516, Caparica, Portugal
| |
Collapse
|
13
|
Glassman PM, Muzykantov VR. Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems. J Pharmacol Exp Ther 2019; 370:570-580. [PMID: 30837281 PMCID: PMC6806371 DOI: 10.1124/jpet.119.257113] [Citation(s) in RCA: 71] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Accepted: 02/26/2019] [Indexed: 12/19/2022] Open
Abstract
The use of drug delivery systems (DDS) is an attractive approach to facilitate uptake of therapeutic agents at the desired site of action, particularly when free drug has poor pharmacokinetics/biodistribution (PK/BD) or significant off-site toxicities. Successful translation of DDS into the clinic is dependent on a thorough understanding of the in vivo behavior of the carrier, which has, for the most part, been an elusive goal. This is, at least in part, due to significant differences in the mechanisms controlling pharmacokinetics for classic drugs and DDSs. In this review, we summarize the key physiologic mechanisms controlling the in vivo behavior of DDS, compare and contrast this with classic drugs, and describe engineering strategies designed to improve DDS PK/BD. In addition, we describe quantitative approaches that could be useful for describing PK/BD of DDS, as well as critical steps between tissue uptake and pharmacologic effect.
Collapse
Affiliation(s)
- Patrick M Glassman
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| | - Vladimir R Muzykantov
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| |
Collapse
|
14
|
Sharifi F, Zhou R, Lim C, Jash A, Abbaspourrad A, Rizvi SS. Generation of liposomes using a supercritical carbon dioxide eductor vacuum system: Optimization of process variables. J CO2 UTIL 2019. [DOI: 10.1016/j.jcou.2018.12.011] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
15
|
Sitar S, Vezočnik V, Maček P, Kogej K, Pahovnik D, Žagar E. Pitfalls in Size Characterization of Soft Particles by Dynamic Light Scattering Online Coupled to Asymmetrical Flow Field-Flow Fractionation. Anal Chem 2017; 89:11744-11752. [PMID: 28974097 DOI: 10.1021/acs.analchem.7b03251] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
An asymmetrical flow field-flow fractionation (AF4) technique coupled to a multiangle light scattering (MALS) detector with an embedded dynamic light scattering (DLS) module was introduced to study the size characteristics and shape of soft particles of various size and type: polystyrene nanosphere size standards, lipid droplets (LDs), and large unilamellar vesicles (LUVs). A range of flow velocities through the LS detector, at which accurate hydrodynamic size can be extracted from the DLS in flow mode, was studied since the particles subjected to a longitudinal flow exhibit not only the Brownian motion due to diffusion but also the translational movement. In addition, the impact of the longitudinal flow velocity on the shape of the artificial LUV of two different sizes and two different compositions was studied by MALS. For comparison, the conventional batch DLS and static light scattering (SLS) experiments without prior sample separation by size were performed. From a combination of batch and flow light scattering results, we concluded that the passage flow velocities at the detector used in this study, 0.2, 0.5, and 1 mL/min, have no significant impact on the shape of spherical vesicles; however, the flow DLS experiments give accurate hydrodynamic radius (Rh) only at the lowest investigated passage flow rate at the detector (0.2 mL/min). With increasing rate of passage flow at the DLS detector, the error in the accuracy of the Rh determination rapidly increases. The error in Rh depends solely on the detector flow rate and particle size but not on the type of the soft particle.
Collapse
Affiliation(s)
- Simona Sitar
- Department of Polymer Chemistry and Technology, National Institute of Chemistry , Hajdrihova 19, 1000, Ljubljana, Slovenia
| | - Valerija Vezočnik
- Biotechnical Faculty, Department of Biology, University of Ljubljana , Večna pot 111, 1000, Ljubljana, Slovenia
| | - Peter Maček
- Biotechnical Faculty, Department of Biology, University of Ljubljana , Večna pot 111, 1000, Ljubljana, Slovenia
| | - Ksenija Kogej
- Faculty of Chemistry and Chemical Technology, Department of Chemistry and Biochemistry, University of Ljubljana , Večna pot 113, 1000, Ljubljana, Slovenia
| | - David Pahovnik
- Department of Polymer Chemistry and Technology, National Institute of Chemistry , Hajdrihova 19, 1000, Ljubljana, Slovenia
| | - Ema Žagar
- Department of Polymer Chemistry and Technology, National Institute of Chemistry , Hajdrihova 19, 1000, Ljubljana, Slovenia
| |
Collapse
|
16
|
Kou J, Dou D, Yang L. Porphyrin photosensitizers in photodynamic therapy and its applications. Oncotarget 2017; 8:81591-81603. [PMID: 29113417 PMCID: PMC5655312 DOI: 10.18632/oncotarget.20189] [Citation(s) in RCA: 291] [Impact Index Per Article: 41.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2017] [Accepted: 07/29/2017] [Indexed: 01/09/2023] Open
Abstract
In 1841, the extraction of hematoporphyrin from dried blood by removing iron marked the birth of the photosensitizer. The last twenty years has witnessed extensive research in the application of photodynamic therapy (PDT) in tumor-bearing (or other diseases) animal models and patients. The period has seen development of photosensitizers from the first to the third generation, and their evolution from simple to more complex entities. This review focuses on porphyrin photosensitizers and their effect on tumors, mediated via several pathways involved in cell necrosis, apoptosis or autophagic cell death, and the preventive and therapeutic application of PDT against atherosclerosis.
Collapse
Affiliation(s)
- Jiayuan Kou
- Department of Pathophysiology, Harbin Medical University, Harbin, PR China.,Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, PR China
| | - Dou Dou
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, PR China
| | - Liming Yang
- Department of Pathophysiology, Harbin Medical University, Harbin, PR China
| |
Collapse
|
17
|
Holzschuh S, Kaeß K, Bossa GV, Decker C, Fahr A, May S. Investigations of the influence of liposome composition on vesicle stability and drug transfer in human plasma: a transfer study. J Liposome Res 2016; 28:22-34. [DOI: 10.1080/08982104.2016.1247101] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Stephan Holzschuh
- Department of Pharmaceutical Technology, Friedrich Schiller University Jena, Jena, Germany and
| | - Kathrin Kaeß
- Department of Pharmaceutical Technology, Friedrich Schiller University Jena, Jena, Germany and
| | | | - Christiane Decker
- Department of Pharmaceutical Technology, Friedrich Schiller University Jena, Jena, Germany and
| | - Alfred Fahr
- Department of Pharmaceutical Technology, Friedrich Schiller University Jena, Jena, Germany and
| | - Sylvio May
- Department of Physics, North Dakota State University, Fargo, ND, USA
| |
Collapse
|
18
|
Tsai WC, Rizvi SS. Liposomal microencapsulation using the conventional methods and novel supercritical fluid processes. Trends Food Sci Technol 2016. [DOI: 10.1016/j.tifs.2016.06.012] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
19
|
The use of asymmetrical flow field-flow fractionation with on-line detection in the study of drug retention within liposomal nanocarriers and drug transfer kinetics. J Pharm Biomed Anal 2016; 124:157-163. [DOI: 10.1016/j.jpba.2016.02.037] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2015] [Revised: 02/12/2016] [Accepted: 02/24/2016] [Indexed: 11/23/2022]
|
20
|
Hinna AH, Hupfeld S, Kuntsche J, Bauer-Brandl A, Brandl M. Mechanism and kinetics of the loss of poorly soluble drugs from liposomal carriers studied by a novel flow field-flow fractionation-based drug release-/transfer-assay. J Control Release 2016; 232:228-37. [PMID: 27112112 DOI: 10.1016/j.jconrel.2016.04.031] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2016] [Revised: 04/21/2016] [Accepted: 04/21/2016] [Indexed: 01/30/2023]
Abstract
Liposomes represent a versatile drug formulation approach e.g. for improving the water-solubility of poorly soluble drugs but also to achieve drug targeting and controlled release. For the latter applications it is essential that the drug remains associated with the liposomal carrier during transit in the vascular bed. A range of in vitro test methods has been suggested over the years for prediction of the release of drug from liposomal carriers. The majority of these fail to give a realistic prediction for poorly water-soluble drugs due to the intrinsic tendency of such compounds to remain associated with liposome bilayers even upon extensive dilution. Upon i.v. injection, in contrast, rapid drug loss often occurs due to drug transfer from the liposomal carriers to endogenous lipophilic sinks such as lipoproteins, plasma proteins or membranes of red blood cells and endothelial cells. Here we report on the application of a recently introduced in vitro predictive drug transfer assay based on incubation of the liposomal drug carrier with large multilamellar liposomes, the latter serving as a biomimetic model sink, using flow field-flow fractionation as a tool to separate the two types of liposomes. By quantifying the amount of drug remaining associated with the liposomal drug carrier as well as that transferred to the acceptor liposomes at distinct times of incubation, both the kinetics of drug transfer and release to the water phase could be established for the model drug p-THPP (5,10,15,20-tetrakis(4-hydroxyphenyl)21H,23H-porphine). p-THPP is structurally similar to temoporfin, a photosensitizer which is under clinical evaluation in a liposomal formulation. Mechanistic insights were gained by varying the donor-to-acceptor lipid mass ratio, size and lamellarity of the liposomes. Drug transfer kinetics from one liposome to another was found rate determining as compared to redistribution from the outermost to the inner concentric bilayers, such that the overall process could be adequately described by a single 1st order kinetic model. By varying the donor-to-acceptor lipid mass ratio in the range 1:1 to 1:10, a correlation was established between donor-to-acceptor-lipid mass ratio and transfer kinetics, which is regarded essential for scaling to physiological lipid mass ratios. By applying the assay to a series of structurally related model compounds of different bilayer affinity, transfer and release kinetics were established over the whole expected range of liposome bilayer associated drugs in terms of water solubility and lipophilicity. A very rapid transfer and considerable release from liposomes to the water phase was observed for the more water-soluble compounds Sudan II (clogP 5.45) and Sudan III (clogP 6.83). For the more lipophilic compounds, the rate of transfer from the donor liposomes followed the rank order Sudan IV (fastest)>Oil Red O>Sudan Black>p-THPP (slowest). For an equimolar donor-to-acceptor lipid mass ratio, half-lifes of transfer in the range of 12min (Sudan IV) up to 1.5h (p-THPP) were determined. In essence, the results presented here allow for both, mechanistic insights and predictions of drug loss from liposomal carriers upon exposure to biological sinks, which appear more realistic than the commonly employed in vitro release tests.
Collapse
Affiliation(s)
- Askell Hvid Hinna
- University of Southern Denmark, Department of Physics, Chemistry and Pharmacy, Campusvej 55, DK-5230 Odense, Denmark
| | - Stefan Hupfeld
- Aker Biomarine Antarctic AS, Oksenøyveien 10, P.O Box 496, NO-1327 Lysaker, Norway; Institute for Energy Technology, Isotope laboratories, Instituttveien 18, P.O. Box 40, NO-2027 Kjeller, Norway
| | - Judith Kuntsche
- University of Southern Denmark, Department of Physics, Chemistry and Pharmacy, Campusvej 55, DK-5230 Odense, Denmark
| | - Annette Bauer-Brandl
- University of Southern Denmark, Department of Physics, Chemistry and Pharmacy, Campusvej 55, DK-5230 Odense, Denmark
| | - Martin Brandl
- University of Southern Denmark, Department of Physics, Chemistry and Pharmacy, Campusvej 55, DK-5230 Odense, Denmark.
| |
Collapse
|
21
|
Quantitative In Vitro Assessment of Liposome Stability and Drug Transfer Employing Asymmetrical Flow Field-Flow Fractionation (AF4). Pharm Res 2015; 33:842-55. [PMID: 26597938 DOI: 10.1007/s11095-015-1831-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2015] [Accepted: 11/16/2015] [Indexed: 02/06/2023]
Abstract
PURPOSE In the present study we introduce an efficient approach for a size-based separation of liposomes from plasma proteins employing AF4. We investigated vesicle stability and release behavior of the strongly lipophilic drug temoporfin from liposomes in human plasma for various incubation times at 37°C. METHODS We used the radioactive tracer cholesteryl oleyl ether (COE) or dipalmitoyl-phosphocholine (DPPC) as lipid markers and (14)C-labeled temoporfin. First, both lipid labels were examined for their suitability as liposome markers. Furthermore, the influence of plasma origin on liposome stability and drug transfer was investigated. The effect of membrane fluidity and PEGylation on vesicle stability and drug release characteristics was also analyzed. RESULTS Surprisingly, we observed an enzymatic transfer of (3)H-COE to lipoproteins due to the cholesterol ester transfer protein (CETP) in human plasma in dependence on membrane rigidity and were able to inhibit this transfer by plasma preincubation with the CETP inhibitor torcetrapib. This effect was not seen when liposomes were incubated in rat plasma. DPPC labels suffered from hydrolysis effects during preparation and/or storage. Fluid liposomes were less stable in human plasma than their PEGylated analogues or a rigid formulation. In contrast, the transfer of the incorporated drug to lipoproteins was higher for the rigid formulations. CONCLUSIONS The observed effects render COE-labels questionable for in vivo studies using CEPT-rich species. Here, choline labelled (14)C-DPPC was found to be the most promising alternative. Bilayer composition has a high influence on stability and drug release of a liposomal formulation in human plasma.
Collapse
|
22
|
Lee BK, Yun YH, Park K. Smart Nanoparticles for Drug Delivery: Boundaries and Opportunities. Chem Eng Sci 2015; 125:158-164. [PMID: 25684780 DOI: 10.1016/j.ces.2014.06.042] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Various pharmaceutical particles have been used in developing different drug delivery systems ranging from traditional tablets to state-of-the-art nanoparticle formulations. Nanoparticle formulations are unique in that the small size with huge surface area sometimes provides unique properties that larger particles and bulk materials do not have. Nanoparticle formulations have been used in improving the bioavailability of various drugs, in particular, poorly soluble drugs. Nanoparticle drug delivery systems have found their unique applications in targeted drug delivery to tumors. While nanoparticle formulations have been successful in small animal xenograft models, their translation to clinical applications has been very rare. Developing nanoparticle systems designed for targeted drug delivery, e.g., treating tumors in humans, requires clear understanding of the uniqueness of nanoparticles, as well as limitations and causes of failures in clinical applications. It also requires designing novel smart nanoparticle delivery systems that can increase the drug bioavailability and at the same time reduce the drug's side effects.
Collapse
Affiliation(s)
- Byung Kook Lee
- Purdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, U.S.A
| | - Yeon Hee Yun
- Purdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, U.S.A
| | - Kinam Park
- Purdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, U.S.A. ; Purdue University, Department of Industrial and Physical Pharmacy, West Lafayette, IN 47907, U.S.A
| |
Collapse
|
23
|
Kaess K, Fahr A. Liposomes as solubilizers for lipophilic parenteral drugs: Transfer of drug and lipid marker to plasma proteins. EUR J LIPID SCI TECH 2014. [DOI: 10.1002/ejlt.201400246] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Kathrin Kaess
- Lehrstuhl für Pharmazeutische Technologie; Institut für Pharmazie, FSU Jena; Jena Germany
| | - Alfred Fahr
- Lehrstuhl für Pharmazeutische Technologie; Institut für Pharmazie, FSU Jena; Jena Germany
| |
Collapse
|
24
|
Vincent N, Ramya DD, Vedha HB. Progress in Psoriasis Therapy via Novel Drug Delivery Systems. Dermatol Reports 2014; 6:5451. [PMID: 25386329 PMCID: PMC4224007 DOI: 10.4081/dr.2014.5451] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2014] [Revised: 06/17/2014] [Accepted: 07/08/2014] [Indexed: 01/08/2023] Open
Abstract
Psoriasis is a lifelong condition which is caused by the negative signals produced by immune system, which leads to hyper proliferation and other inflammatory reactions on the skin. In this case, keratinocytes which are the outermost layer of skin possess shortened life cycle and results in the alteration of desquamation process where the cytokines will come out through lesions of affected patients and as a result, scaling marks appears on the skin. These conditions may negatively affect the patient’s quality of life and lead to psychosocial stress. Psoriasis can be categorized as mild, moderate and severe conditions. Mild psoriasis leads to the formation of rashes, and when it becomes moderate, the skin turns into scaly. In severe conditions, red patches may be present on skin surface and becomes itchy. Topical therapy continues to be one of the pillars for psoriasis management. Drug molecules with target effect on the skin tissues and other inflammations should be selected for the treatment of psoriasis. Most of the existing drugs lead to systemic intoxication and dryness when applied in higher dose. Different scientific approaches for topical delivery are being explored by researches including emollient, modified gelling system, transdermal delivery, spray, nanogels, hydrogels, micro/nano emulsion, liposomes, nano capsules etc. These topical dosage forms are evaluated for various physico chemical properties such as drug content, viscosity, pH, extrudability, spreadability, toxicity, irritancy, permeability and drug release mechanism. This review paper focus attention to the impact of these formulation approaches on various anti-psoriasis drugs for their successful treatment.
Collapse
Affiliation(s)
- Nitha Vincent
- Department of Pharmaceutical Technology, School of Chemical and Biotechnology, SASTRA University , Thanjavur, India
| | - Devi D Ramya
- Department of Pharmaceutical Technology, School of Chemical and Biotechnology, SASTRA University , Thanjavur, India
| | - Hari Bn Vedha
- Department of Pharmaceutical Technology, School of Chemical and Biotechnology, SASTRA University , Thanjavur, India
| |
Collapse
|
25
|
Winter P. Molecular Imaging at Nanoscale with Magnetic Resonance Imaging. Nanomedicine (Lond) 2014. [DOI: 10.1201/b17246-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
26
|
|
27
|
Reshetov V, Lassalle HP, François A, Dumas D, Hupont S, Gräfe S, Filipe V, Jiskoot W, Guillemin F, Zorin V, Bezdetnaya L. Photodynamic therapy with conventional and PEGylated liposomal formulations of mTHPC (temoporfin): comparison of treatment efficacy and distribution characteristics in vivo. Int J Nanomedicine 2013; 8:3817-31. [PMID: 24143087 PMCID: PMC3797282 DOI: 10.2147/ijn.s51002] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
A major challenge in the application of a nanoparticle-based drug delivery system for anticancer agents is the knowledge of the critical properties that influence their in vivo behavior and the therapeutic performance of the drug. The effect of a liposomal formulation, as an example of a widely-used delivery system, on all aspects of the drug delivery process, including the drug’s behavior in blood and in the tumor, has to be considered when optimizing treatment with liposomal drugs, but that is rarely done. This article presents a comparison of conventional (Foslip®) and polyethylene glycosylated (Fospeg®) liposomal formulations of temoporfin (meta-tetra[hydroxyphenyl]chlorin) in tumor-grafted mice, with a set of comparison parameters not reported before in one model. Foslip® and Fospeg® pharmacokinetics, drug release, liposome stability, tumor uptake, and intratumoral distribution are evaluated, and their influence on the efficacy of the photodynamic treatment at different light–drug intervals is discussed. The use of whole-tumor multiphoton fluorescence macroscopy imaging is reported for visualization of the in vivo intratumoral distribution of the photosensitizer. The combination of enhanced permeability and retention-based tumor accumulation, stability in the circulation, and release properties leads to a higher efficacy of the treatment with Fospeg® compared to Foslip®. A significant advantage of Fospeg® lies in a major decrease in the light–drug interval, while preserving treatment efficacy.
Collapse
Affiliation(s)
- Vadzim Reshetov
- Université de lorraine, centre de Recherche en Automatique de Nancy, Campus Sciences, Vandœuvre-lès-Nancy, France ; Centre National de la Recherche Scientifique, Centre de Recherche en Automatique de Nancy, France ; Laboratory of Biophysics and Biotechnology, Physics Faculty, Belarusian State University, Minsk, Belarus
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
|